HIGHLIGHTS
SUMMARY
Dalbavancin (DBV) is a semi-synthetic, novel, long-acting lipoglycopeptide active against Gram-positive pathogens, including multi-drug resistant isolates, approved for the treatment of ABSSSIs. Dunne et_al found a mean bone/plasma AUC of 13.1%, suggesting that two doses of DBV 1500 mg infusion administered one week apart may provide tissue exposure over the MIC for Staphylococcus aureus for 8 weeks. The aim of this work was to better describe DBV PK in real-life settings and to characterise its PK/PD profile, for both approved and unapproved indications, treated with either . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.